pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update
The pan-Canadian Pharmaceutical Alliance Office (pCPAO) updated the status of negotiations on brand name drugs as of February 28, 2017.
- There are currently 33 negotiations underway with one new file – Eylea (aflibercept) was added since the last update on January 31, 2017.
- There have been 142 joint negotiations completed with 8 files successfully negotiated since the last update of January 31, 2017:
- Daklinza (daclatasvir): Used to treat chronic Hepatitis C infection
- Epclusa (sofosbuvir/velpatasvir): Used to treat chronic Hepatitis C infection
- Harvoni (sofosbuvir/ledipsavir)* (second letter of intent): Used to treat chronic Hepatitis C infection
- Plegridy (PegIFN beta-1a): Used to treat relapsing-remitting multiple sclerosis (RRMS)
- Sovaldi (sofosbuvir)* (second letter of intent): Used to treat chronic Hepatitis C infection
- Sunvepra (asunaprevir): Used to treat chronic Hepatitis C infection
- Technivie (ombitasvir/ paritaprevir/ ritonavir): Used for the treatment of Hepatitis C (genotype 4)
- Zepatier (elbasvir grazoprevir): Used for the treatment of Hepatitis C (genotype 1, 4)
- There continues to be 49 drug products for which the pCPA has decided not to negotiate collectively or individually at the provincial-territorial level as of February 28, 2017.
- There remains 13 negotiations for brand name drug products that have been recommended by the pCPA to be considered by each Province/Territory individually with no new files added since the last update of February 28, 2017.
Please visit the pCPA website for more information.
To receive updates similar to this one please be sure to sign up for Market Access Signals, our free e-mail newsletter service.
